Shares of Genocea Biosciences Inc. (NASDAQ:GNCA) traded up 4.1% during mid-day trading on Tuesday . The stock traded as high as $5.37 and last traded at $5.35, with a volume of 82,497 shares. The stock had previously closed at $5.14.

Several analysts recently issued reports on the company. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a research note on Monday, August 8th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $17.95.

The company’s market capitalization is $152.72 million. The company has a 50 day moving average of $4.62 and a 200 day moving average of $4.52.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. Equities research analysts anticipate that Genocea Biosciences Inc. will post ($1.63) EPS for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.